Skip to main content

Table 3 Adjusted overall survival and progression-free survival of patients by multivariate Сox regression analyses

From: A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study

Variables OS PFS
HR (95% CI) p-value HR (95% CI) p-value
Neoadjuvant chemotherapy 1.367 (0.806–2.319) 0.246 1.136 (0.770–1.678) 0.521
Maintenance therapy with I3C 0.272 (0.147–0.502) < 0.0001 0.309 (0.202–0.472) < 0.0001
Maintenance therapy with I3C and EGCG 0.244 (0.150–0.396) < 0.0001 0.241 (0.172–0.339) < 0.0001
PСI (> 25 vs ≤ 25) 2.829 (1.813–4.415) < 0.0001 2.114 (1.589–2.812) < 0.0001
FIGO stage (IV vs III) 9.642 (5.963–15.592) < 0.0001 6.953 (4.744–10.190) < 0.0001
Secondary debulking surgery < 0.0001 (< 0.0001- > 1.0х103) 0.930 1.277 (0.875–1.862) 0.205
  1. OS overall survival, PFS progression-free survival, HR hazard ratio, 95% CI 95% confidence interval, I3C indole-3-carbinol, EGCG epigallocatechin-3-gallate, PCI peritoneal cancer index, FIGO International Federation of Gynecology and Obstetrics
  2. NOTE. Bold font indicates p < 0.05
\